BARD1 Life Sciences Ltd (ASX:BD1) chief executive Dr Leearne Hinch updates Proactive Investors on the Perth-based medical technology company’s progress in developing and commercialising diagnostics for the early detection, and possibly treatment, of cancer.
"Our company offers quite a broad patent portfolio, which other companies don't necessarily have. We have two cancer tests in the pipeline. We've also got extremely good results across multiple studies validating the accuracy of our two cancer diagnostics, for both lung cancer and ovarian cancer. So, what we offer is a pipeline rather than just one diagnostic test, and importantly our BARD1 biomarkers can actually be applied to multiple cancers, including breast cancer and prostate cancer, and other cancers," says Hinch.
"BARD1 has got a broad patent portfolio which covers BARD1 DNA and protein sequences. It also covers both diagnostic and therapeutic methods across various cancers. During this last quarter, we had both a Japanese and an Israeli provisional patent granted, so that strengthens our portfolio such that we now have eight granted patents across the portfolio and 20 pending patents," Hinch continues.
The company recently completed a capital raising of $1.3 million to strengthen its cash position ahead of the next phase of research and development. Hinch explains, "BARD1's focus now is on moving to the next development stage, which is where we transfer our research assay to a commercial platform. That's a very important milestone for the company.”